• Roth’s Healthcare Private Company Forum is currently taking place
• The investor-focused forum will feature a series of corporate fireside chats
• The conference will also play host to three investment panels

Today, Roth Capital Partners (“Roth”) is hosting the Virtual Healthcare Private Company Forum. The event, which is now fully underway, features a number of different healthcare companies drawn from across the biotechnology, pharmaceuticals, and medical technologies verticals. Roth has long been renowned for their experience and ever-growing network within the global healthcare industry, having been involved in more than 530 transactions for its healthcare clients since 2010, with a total transaction value of upwards of $24 billion. With the medical industry and emerging therapeutics sector evolving at a break-neck pace, Roth has sought to host the Healthcare Private Company Forum, providing executive management teams representing established private healthcare companies from across the medical industry an invaluable opportunity to meet and share their respective stories with attendees. “We are excited to host our Virtual Healthcare Private Company Forum for private companies. As the event continues to grow, we are bringing together a broader range of private healthcare companies, from across the US and beyond, to tell their stories,” said James Antonopoulos, Managing Director & Head of Healthcare Investment Banking at Roth. “This event is another example of Roth’s continued leadership in supporting the growth of healthcare companies, including biotechnology, specialty pharmaceuticals, medical devices & diagnostics.” The Roth conference will feature a series of fireside chats, with companies set to address a series of pertinent topics relating to the field of emerging therapeutics. These will include:

• Active Motif: “Enabling Tools and Services for Epigenetics and Gene Regulation Research”
• Aruna Bio: “Utilizing Exosomes to Cross the Blood/Brain”
• Cullgen: “Powering Protein Degradation for Tomorrow’s Medicines”
• Dyve Biosciences: “Breakthrough Drug Delivery Technology Expands Transdermal Therapeutic Options”
• Intensity Therapeutics: “Unprecedented Improvement Upon Intratumoral Injection”
• Reva Medical: “Bioresorbable Polymer Technologies for Vascular Applications”
• Ryvu Therapeutics: “Novel Small Molecule Therapies Addressing High-Value Oncology Indications”

Moreover, the conference will also play host to three discussion panels, featuring leading companies involved within the respective sectors and moderated by Roth research analysts. The panels will touch upon topics such as “Novel Approaches to Tumor Eradication”; “Natural Killer Cell Approaches to Eradicate Tumors”, and the “Next Wave of Psychedelic Drug Developers.” By showcasing some of the industry’s most cutting-edge and privately held companies, Roth Virtual Healthcare Private Company Forum is providing attendees with an invaluable opportunity to discover a number of exciting and innovative companies. For more information about the Roth Virtual Healthcare Private Company Forum, visit www.roth.com/healthcareprivateday

• Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices
• RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain
• Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating

Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. In a recent article, RYAH outlined the history of cannabis clinical trials compared to how they are conducted in 2021. The full report can be found at https://ibn.fm/wwPrP. It’s interesting to note that most cannabis studies have been anti-cannabis, focusing on cannabis-related crime, intoxication/abuse, and use among adolescents until recently. Instead of looking to this plant for its medicinal benefits, the focus has been on its potentially harmful effects. Today, research teams are exploring the use of cannabis to address chronic conditions, especially for pain relief. In the past, studying the plant was complex and controlling dose size and strain profile problematic. In 2019, RYAH began commercializing its smart inhaler solution. Since then, it has created an ecosystem of IoT products, each with three elements: dose-measuring device, medicine-carrying component and a mobile application. The Smart inhaler is the first dry-herb inhaler of its kind where the user can track and control the amount inhaled. This allows for more consistent and predictable results. The connected Health App allows for stat-tracking and presets for both temperatures and dosing, both of which can be adjusted to the user’s needs. The collection of the data provides for efficacy analysis and adjustments to future treatments. RYAH has begun to work with an international oncology clinic in the UK on one of the largest clinical trials of its kind. The company will be studying the safety and efficacy of cannabis and hemp for the treatment of chronic pain. Recently the company successfully shipped 10,000 dry-herb cartridges and QR codes in its initial shipment for the clinic’s pilot run. The complete order includes potentially thousands of RYAH Smart inhalers and millions of proprietary cartridges for the use of this study over the next five years. The future for cannabis study with the addition of dose-measuring devices looks promising. RYAH has found over 400 studies on cannabis that are currently in the recruitment or study phase in the U.S., with more in Canada, the U.K., and Israel. The plant’s many therapeutic benefits are finally being explored, and the potential for creating better treatment plans for patients with various medical conditions is high. Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating. As the perception of cannabis changes in the public eye, so do the opportunities for developing more clinical trials focused on this plant’s therapeutic potential. To learn more about this company, visit  www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• The public education system, where roughly 90% of students are enrolled, isn’t working.
• No amount of resources can change the problems facing the public school system.
• The Emaginos solution is focused on engaging students by providing a customized education for every child and hands-on learning opportunities.

Grades have been turned in, and the public school system has failed — at least in the area of science. According to the National Assessment of Educational Progress (“NAEP”) science assessment, only 36% of 4th graders were proficient in science in 2019, with 35% of 8th graders reaching proficiency and significantly fewer — 22% — 12th graders testing at or above a proficient level in science (https://ibn.fm/kVDuq). These are the type of results that Emaginos Inc., a REG-A company with news posted on Yahoo Finance, is determined to change. (See the company’s website if interested in investing.) “These findings are more than just an embarrassment for those who run our nation’s educational systems,” a recent article noted. “They serve as yet another reminder that the public education system, where roughly 90% of students are enrolled, isn’t working. Indeed, a perusal of the report card’s sub-data shows that while results across the board aren’t great, public school students’ test scores are significantly lower than students enrolled in Catholic private schools, for one example.” And earmarking more money isn’t the answer, the article goes on to point out. “Economic research shows no clear correlation between public education spending and outcomes,” the article states. “If throwing more taxpayer money at the problem could accomplish anything, we wouldn’t have such abysmal results. The truth is that no amount of resources can change the structural problems facing the public school system. ‘Pouring more money into the same broken system won’t fix the deeper problem — government monopolies have weak incentives to cater to the needs of their customers by spending money wisely.’” The Emaginos solution doesn’t require additional money or other resources to fix the system; in fact, the company supports public schools and restores the concept of neighborhood schools being the center of communities. Even more important, the Emaginos Discovery Learning System is focused on engaging students by providing a customized education for every child and hands-on learning opportunities. “Emaginos considers every child as special and at risk — some at greater risk than others,” the company explains (https://ibn.fm/kk5Dj). “We deliver a customized education to each child based upon a continuous improvement model. Our students master the academic content and high-performance skills without teaching to the test.” For more information about Emaginos and to learn about investment and shareholder opportunities, visit www.Emaginos.com. NOTE TO INVESTORS: The latest news and updates relating to Emaginos are available in the company’s newsroom at https://ibn.fm/Emaginos

• Quality, value, diversity hallmarks of EV grand opening event.
• IMC has existing inventory already on hand, doesn’t require substantial amount of capital before seeing profitability.
• Company offers affordable vehicles with emphasis on great design, a green mindset, performance and functionality.

DSG Global (OTCQB: DSGT), an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors, and subsidiary Imperium Motor Company (“IMC”) unveiled more than two dozen electric-powered vehicles at the grand opening of the Imperium Motors Experience Center in Fairfield, California (https://ibn.fm/BGwLh). Held June 18–19, the grand opening event included interviews, press coverage, test drives, snacks and a chance to win an E-Rover. “While we are confident that potential customers will be impressed with the quality and value of our vehicles, they may be surprised by the diversity of our product offering and some of the new vehicle models we will unveil in the near future,” said IMC president Rick Curtis prior to the event. “We look forward to providing an educational and rewarding experience for all visitors.” Designed to create interest in IMC’s impressive line of EVs, the event encouraged attendees to drive and ride in 25 different electric-powered units, including the company’s flagship Imperium ET5 SUV, the Van Maxx, the Urbee 4, the new Jonway T3 Cargo, the Urbee Security LSV, the Raptor Golf Cart, the Rumble lineup, the Imp Chimp and other models. Unlike many companies jockeying for position in the EV space, IMC has existing models and inventory already on hand, ready to be sold. This means the company doesn’t require a substantial amount of capital in order to see profitability. “We are confident that we have one of the most diverse product lineups in the electric vehicle industry,” said Curtis (https://ibn.fm/aRaOA). “There are very few other vehicles at our price point that include the standard equipment and functionality that we can offer. IMC is an EV sales, manufacturing and marketing company that offers affordable vehicles equipped for the North American market with emphasis on great design, a green mindset, performance and functionality. Available vehicles include high-speed, mid-speed and low-speed cars, trucks, SUVs, vans, buses and scooters. Many models were available for purchase at the grand opening of the experience center, while others were available for order. DSG Global is an emerging global technology company with an array of interconnecting businesses in some of the fastest-growing market sectors. With roots in the golf industry, in which it specializes in fleet management with patented analytics, mobile touch-screen engagement and electric golf carts under the VTS brand, the company is moving quickly with road-ready electric vehicles for sale in the first quarter of 2021 through its Imperium Motor Company subsidiary. To learn more about the company, please visit www.DSGTGlobal.com. NOTE TO INVESTORS: The latest news and updates relating to DSGT are available in the company’s newsroom at https://ibn.fm/DSGT

• SHRG’s global expansion efforts will be the Happy Co.’s first introduction into the European market.
• Company planning to release entire U.S. product line on an NFR basis to customers in 21 European countries.
• Proprietary nootropic products are nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value.

Sharing Services Global (OTCQB: SHRG) has announced that its wholly owned subsidiary, the Happy Co., is preparing to launch into 21 European countries with its exclusive, high-quality products. The Happy Co. is a leading producer and distributor of nootropic, functional beverage products with a focus on health and wellness. “Our global expansion efforts with these not-for-resale (‘NFR’) products will be the Happy Co.’s first introduction into the European market,” said Elevacity International Holdings CEO Bo Short (Elevacity is the parent company of the Happy Co.). “We are taking advantage of the popularity and results of instant-impact Happy Co. products in the U.S. and collaborating with a new team in Europe to leverage motivating growth for the company.” The Happy Co. is planning to unveil its entire U.S. product line on an NFR basis to customers in 21 countries across Europe in the coming weeks. The company anticipates making products available for purchase in Austria, Belgium, Czech Republic, Denmark, England, France, Germany, Greece, Hungary, Ireland, Italy, Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Spain, Sweden, Switzerland and Wales. The Happy Co. offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat, tighten skin, and make you look, feel and perform like a younger person. The products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. “As we continue to focus on our mission of growing our company internationally, we will be spreading the spirit of collaboration and happiness to exciting new markets across Europe,” said Happy Co. president Garrett McGrath. “We look forward to providing our most popular products to new customers in Europe and learning more about how we can make a positive impact on their lives.” Formerly Elepreneurs, the Happy Co. launched in February 2021 with an established foundation of successful nootropic, functional beverage products. Although the company does produce superior products, its mission is to provide business partners and consumers with much more than that. “We are a lifestyle and a dose of happy,” the company’s slogan proclaims. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics
• The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation
• The book mainly covers craniofacial growth and developmental Genetics
• It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”)

Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from years of research and has been instrumental in treating the condition among adults. Dr. G. Dave Singh, the personality behind Vivos Therapeutics, shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product in his new book titled Pneumopedics and Craniofacial Epigenetics. He details his research’s progress and Vivo Therapeutics’ achievements over the years. Dr. Singh’s primary goal with this book is to spread the word far and wide about the technology, how it can help people think about health conditions such as OSA, and how such ailments are treated going forward. He covers craniofacial growth along with developmental Genetics. By doing so, he addresses the link between dentofacial anomalies and developmental deficiencies that are associated with downstream conditions including, but not limited to OSA. Dr. Singh also cements the scientific and biological foundation upon which Vivos Therapeutics’ proprietary approach rests. By so doing, he sheds more light on OSA while offering some incredible insights into the future of mild-to-moderate OSA diagnosis and treatment. According to Vivos Life, over 80% of people who suffer from the effects of this condition do not know that they have it. Dr. Singh hopes that he will sensitize people about the disease with his new book, inform them both on how to identify it and how to treat it effectively. As a leading professor and researcher in the sleep medicine field, Dr. Singh understands the value of sharing knowledge and research. This book is a blend and an improvement on the over 200 peer-reviewed medical articles he has written throughout his career (https://ibn.fm/RVZsQ). It is also a way to share the strides that both he and Vivos Therapeutics Inc. have made regarding the treatment of mild-to-moderate OSA. Vivos Therapeutics Inc.’s primary focus is developing and commercializing innovative diagnostic and treatment modalities for patients dealing with sleep-disordered breathing, including mild-to-moderate OSA. Its core mission is to rid the world of mild-to-moderate OSA, and the Vivos System is a significant clinical breakthrough on that front. Dr. Singh’s book is a chronicle of the process that ultimately led to the innovation of the Vivos System and how important the invention is to the treatment of OSA.

• Knightscope develops and manufactures autonomous security robots that utilize an array of technological tools to patrol and monitor client properties on a 24/7 basis
• The company’s robots have provided more than a million hours of service to clients since 2015, and recently got high-profile attention through an appearance on the Disney+ streaming superhero series “Loki”
• Knightscope’s ASR robots are dedicated to helping make the United States safer as a whole, providing video and audio data reception, transmission and analysis, to determine if security concerns and the need for crime deterrence or other emergency intervention are present

When Knightscope’s K5 model autonomous security robot (“ASR”) appeared recently in the second episode of the Disney+ superhero streamer “Loki,” it was cast in a futuristic role that had it roaming the aisles of a big box store in the year 2050 (https://ibn.fm/ZtjZQ). But the AI-equipped Knightscope ASRs are very much a part of our present society, having logged over a million hours of service since 2015 with paying clients, patrolling busy parking lots/structures, shopping malls, hospitals, city parks and corporate campuses across the United States. Knightscope’s ASRs come in a variety of models. The K5 is designed to function in outdoor environments, performing property security functions in a fully autonomous manner. The K5 may utilize LiDAR, SONAR, GPS and wheel odometer technology to move about its environment recognizing potential obstacles and hazards. Its surveillance capabilities function through video and audio data that are monitored and recorded in 360 degrees, as well as infrared and thermal scanning in dark conditions, broadcast signal detection, and select image recognition features. It can communicate with people in its environment through pre-recorded messages, live-streaming text-to-audio technology, and directed audio transmissions. And the Loki episode was perhaps an example of the company’s discretion with clients — the company’s social media posts noted that, after “over a year of keeping our mouths stapled, glued and taped shut,” it could finally talk about its part in the Marvel Cinematic Universe’s multiverse following the airing of the episode (https://ibn.fm/AUd6C). Property security continues to remain a significant concern for corporate and government clients. As of June 20, Wikipedia listed just shy of 300 mass shooting events in the United States since the beginning of the year that have led to the deaths of nearly 350 people and injuries for more than 1,200 people (https://ibn.fm/tqnrJ). None of this year’s incidents up to that date have been school related, but the country’s history of occasional gun violence targeting children and school administrators during school hours — particularly since the April 1999 killings at Colorado’s Columbine High School — has driven municipal efforts to provide more technologically enhanced security measures at schools nationwide. In a recent example, Ohio’s governor announced June 16 that more than $10 million in state-based grants will be awarded to fund security enhancements at K-12 public schools and institutions of higher education in the state this year and early next year (https://ibn.fm/UxuhP). “It’s important that we work proactively to ensure that our school buildings and grounds are as safe as possible to protect both students and staff,” Governor Mike DeWine stated. “Two new grant programs offered through the Ohio School Safety Center will help schools and universities pinpoint any weaknesses in their physical security and make needed improvements and upgrades.” In May, a Utah teacher was hailed as a hero for preventing a man from kidnapping an 11-year-old girl or harming other students on an elementary school playground after the teacher saw the stranger behave aggressively and rushed out to respond to the situation (https://ibn.fm/iPDsp). Knightscope has declared its mission to make the nation safer through vigilance and a non-threatening IP. “A violent crime occurs every four seconds and a property crime every 25 seconds. … Crime has more than a trillion-dollar negative economic impact on the U.S. every single year,” Knightscope founder and CEO William Santana Li said in a YouTube video about the company earlier this year (https://ibn.fm/MRztb). “The ongoing mass shooting violence across the country is not acceptable. That is why I put in 80-100-hour weeks to do something meaningful about it.” For more information, visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/Demo. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• In 2021, Tryp Therapeutics plans on expanding its academic collaborations
• It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations
• Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery
• A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both for patients and targeted ailments. In a podcast, Greg McKee, chairman and CEO of the company, candidly shared Tryp’s position on the treatment of diseases with unmet medical needs through the use of psychedelics such as psilocybin (https://nnw.fm/rL6Sv) (https://ibn.fm/wXQNy). McKee noted that the company has identified its prospective patients and targeted indications. Narrowing both of these down, he said, allows the company to maintain focus, allowing for the patients’ situations to be adequately served and new solutions to be identified. The company’s primary focus is on chronic pain indications such as fibromyalgia, phantom limb pain, and complex regional pain syndrome, as well as certain eating disorders such as binge eating and hypothalamic obesity. “All these subcategories of chronic pain are areas where there is a significant unmet medical need. In other words, situations where patients aren’t properly served,” McKee noted (https://nnw.fm/rL6Sv) (https://ibn.fm/wXQNy). Tryp Therapeutics is a pharmaceutical company committed to developing compounds for diseases with high unmet medical needs through accelerate regulatory pathways (https://nnw.fm/AV0gy) (https://ibn.fm/uk2da). The company sees innovation as being key to addressing patient needs that are not being met by existing treatment options. “We see that there is a great need to innovate around the specific dose and the specific route of administration [of psychedelic compounds]. Drugs are delivered in a lot of different ways and, up to this point historically, psilocybin and most of the other chemistries in the psychedelics space have all been oral pills,” McKee noted. Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state. The underlying goal is to increase the brain’s neuroplasticity and encourage proper connectivity among neural networks. “We’re excited to innovate around the route of administration and controlled dosing so that patients have the proper kind of experience that ultimately addresses their particular illness,” McKee said. Tryp Therapeutics has created a strong foundation for the identification and treatment of orphan and other diseases. In 2021, the company plans on expanding its academic collaborations and initiating multiple Phase 2a clinical studies to determine the efficacy of its drug products in patient populations. This will be the first time that psilocybin is used for several indications in a clinical trial, marking a significant milestone not just for Tryp Therapeutics but also for psychedelic drug development. “We anticipate having at least two Phase 2a clinical trials up and running in 2021 and potentially more based on the breadth of academic collaborations we have underway. That will set us up to potentially see signals of efficacy in these patient populations for the first time,” commented McKee (https://nnw.fm/rL6Sv) (https://ibn.fm/wXQNy). For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://nnw.fm/TRYPF https://ibn.fm/TRYPF

• Magazine article plugs cooling-off benefits of cannabis.
• Science actually points to different physiological mechanisms that allow cannabis to help lower body temperatures.
• The cannabis cooling article is only one of several offerings in the summer issue of the Chalice magazine.

With record heat engulfing the West for the past couple of weeks and temperatures topping 100 degrees in California, Oregon, Arizona, Nevada and Utah (https://ibn.fm/Und6A), people are searching for relief. Chalice Brands (CSE: CHAL) (OTCQB: CHALF) has an answer: Beat the heat this summer with temperature-fighting cannabis. According to a Chalice magazine article, titled “Cannabis Is Really Cool,” there is good news for cannabis enthusiasts who are sweltering in the sun. “Our favorite plant might keep you feeling calm, cool and collected,” the article reports (https://ibn.fm/M0eX9). “In addition to getting you high, cannabis can keep you cool. Science guides us to a few different physiological mechanisms that allow cannabis to help lower body temperatures. “Cannabinoids, compounds found in cannabis, can interact with the hypothalamus and endocannabinoid system and subsequently impact temperature regulation while also occupying the vanilloid receptor family (TRPA-1. TRPM8, etc.),” the article continues. “If you missed the vanilloid receptor family lesson in biology class, don’t worry, we did too. But now, thanks to our interest in cannabis, we know the vanilloid receptors alter our perception of heat and pain and, therefore when also engaged by cannabinoids, may numb our sensation of heat and feeling hot. “Of course, we do not suggest that you only turn to cannabis if you’re feeling overheated,” the article concluded. “Be the reasonable, intelligent adult we know you are, and make sure you’re doing things like drinking water and finding shade or air conditioning. But hey, if this is another excuse to consume a little bit more cannabis, we’ll take it!” The cannabis cooling article isn’t the only thing worth reading in the summer issue of the Chalice magazine. The online publication also shares tips for eating edibles for those who are new to the world of cannabis, five ways to incorporate cannabis into summer plans, and an ooey-gooey chocolate chip recipe—which includes a couple of cannabis ingredients, of course. For Oregonites who want to test the cannabis cooling theory for themselves, Chalice is building a strong presence in Oregon. A premier consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, Chalice has 12 dispensaries in Portland, Oregon. The company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness. Chalice operates nationally through Fifth and Root and has operations in Oregon and California. To learn more about this company, visit www.ChaliceBrandsLtd.com. NOTE TO INVESTORS: The latest news and updates relating to CHALF are available in the company’s newsroom at https://ibn.fm/CHALF

• Silver prices rose by 29% YoY in 2020, led by an 8% increase in physical investment demand
• The World Silver Survey 2021 has forecast total silver demand to rise by 15% in 2021 to 1.03 billion ounces, with industrial silver consumption set to bounce back by 8% YoY
• The rosy demand outlook contrasts against silver’s tenuous supply profile, with annual mining production declining for a fourth consecutive year in 2020
• Excellon Resources is among the leaders in the search for new silver deposits, with a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration

Silver has long been recognized as the world’s best conductor of energy, and electric vehicles as well as solar power-led photovoltaics are set to serve as major demand drivers for the metal over the coming years (https://ibn.fm/nQVtP). Nonetheless, the onset of the pandemic and resulting slowdown in global economic conditions led industrial silver demand to fall by 5% in 2020 to a five-year low of 486.8 million ounces, a decline which was countermanded to a certain extent by a sharp increase in physical investment demand for the precious metal. In fact, investor demand for silver bars and coins rose by 8% last year to a four-year high of 200.5 million ounces. Resurgent industrial demand in 2021, coupled with ongoing physical investment demand, are set to bode positively for companies such as Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with precious metal projects in Mexico, Idaho and Germany. The Silver Institute’s World Silver Survey 2021 revealed that silver prices had risen by 27% between 2019 and 2020, with the precious metal trading at an annual average of $20.55 an ounce over the past year. The price rally was largely fueled by a surge of net inflows into silver-backed exchange-traded products (“ETPs”), with investment vehicles seeing underlying holdings of the precious metal rise by 331.1 million ounces over the course of 2020 (https://ibn.fm/LvXzw), taking overall global holdings above one billion ounces for the first time since ETPs were first introduced in 2006. Remarkably, the rise in investment demand came amidst an 85% plunge in Indian silver investment demand, traditionally a mainstay of global investment demand for the precious metal. The World Silver Survey has forecast a rise in total silver demand in 2021 of 15% to 1.03 billion ounces, with industrial demand set to rebound by 8% year-over-year. However, the rosy demand outlook contrasts against the commodity’s rapidly declining supply profile. In 2020, global mine production registered its fourth consecutive annual decline, with silver output declining by 5.9% to 784.4 million ounces. The decline was primarily driven by a reduction in production from primary silver mines. These mines, which accounted for 27% of total silver production last year, saw output fall by 11.9% year-over-year to 209.4 million ounces. This decline was further exacerbated by temporary mine closures across a host of major silver producing countries in the first half of 2020 (https://ibn.fm/C7Bix). An ongoing reduction in global mine output has lent more urgency to the search for fresh silver supplies. Excellon Resources has been a key driver of the movement, currently working towards developing a precious metals growth pipeline across a diverse range of geographies including Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho boasting strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany. A dearth of new silver deposit discoveries, coupled with resurgent industrial and physical investment demand, may eventually lead to a production squeeze for the precious metal. Should that eventuality come to fruition, Excellon Resources looks well positioned to capitalize on it. For more information, visit the company’s website at www.ExcellonResources.com. NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN